Moberg Pharma (MOB) Investor presentation summary

Product overview and differentiation

• TerclaraⓇ is a novel topical terbinafine treatment for mild to moderate nail fungus in adults, approved in 13 European countries.

• Delivers terbinafine directly to the nail, achieving 1000x higher concentration in the nail and 40x in the nail bed compared to oral treatment, with negligible systemic absorption.

• Achieves a best-in-class mycological cure rate of 76%, matching oral terbinafine and outperforming other topical competitors.

• Offers rapid visible improvement, easy application, and a favorable safety profile with no risk of systemic side effects.

• Features differentiated packaging and does not require nail filing or lacquer removal.

Market position and commercial performance

• Achieved market leadership in Sweden and Norway, driving category growth and increasing market share significantly in both countries.

• Awarded 'Launch of the Year 2024' in Sweden and nominated for the same in Norway, recognized for innovation and strong sales.

• Holds a strong premium position due to superior cure rates, supporting higher pricing compared to competitors.

• Partners with Karo for EU distribution (excluding Sweden and Norway), covering 19 countries and reaching 500 million citizens.

• Commercial success builds on proven models and previous launches, such as Kerasal Nail® in the US.

Clinical evidence and regulatory status

• Supported by two Phase 3 studies (over 800 patients) meeting primary endpoints, demonstrating high cure rates and safety.

• Approved as an OTC or Rx product in major European markets, with additional approvals pending.

• Global patent protection until 2032, with ongoing applications.